1-naphthyl isothiocyanate decreases expression EXP 6480464 1-Naphthylisothiocyanate results in decreased expression of HACL1 mRNA CTD PMID:30723492 17beta-estradiol increases expression ISO RGD:1553280 6480464 Estradiol results in increased expression of HACL1 mRNA CTD PMID:19484750 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions EXP 6480464 [3 more ... CTD PMID:16984957 2,2',4,4'-Tetrabromodiphenyl ether affects expression ISO RGD:1553280 6480464 2 more ... CTD PMID:30294300 2,3,7,8-tetrabromodibenzodioxine increases expression ISO RGD:1553280 6480464 2 more ... CTD PMID:27604104 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1553280 6480464 [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of HACL1 mRNA, AHR protein promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of HACL1 mRNA] CTD PMID:19759094 , PMID:25975270 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of HACL1 mRNA CTD PMID:20959002 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of HACL1 mRNA CTD PMID:22298810 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1553280 6480464 Tetrachlorodibenzodioxin results in increased expression of HACL1 mRNA CTD PMID:18796159 more ... 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of HACL1 mRNA CTD PMID:21346803 2,6-dinitrotoluene affects expression EXP 6480464 2, 6-dinitrotoluene affects the expression of HACL1 mRNA CTD PMID:21346803 3,3',4,4',5-pentachlorobiphenyl multiple interactions EXP 6480464 [3 more ... CTD PMID:16984957 3,3',4,4',5-pentachlorobiphenyl decreases expression EXP 6480464 3 more ... CTD PMID:20959002 3H-1,2-dithiole-3-thione decreases expression EXP 6480464 1, 2-dithiol-3-thione results in decreased expression of HACL1 mRNA CTD PMID:19162173 4,4'-sulfonyldiphenol increases expression ISO RGD:1553280 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of HACL1 mRNA CTD PMID:33297965 4-hydroxyphenyl retinamide decreases expression ISO RGD:1553280 6480464 Fenretinide results in decreased expression of HACL1 mRNA CTD PMID:28973697 acetamide decreases expression EXP 6480464 acetamide results in decreased expression of HACL1 mRNA CTD PMID:31881176 aconitine increases expression EXP 6480464 Aconitine results in increased expression of HACL1 protein CTD PMID:33236894 aflatoxin B1 affects expression ISO RGD:1607054 6480464 Aflatoxin B1 affects the expression of HACL1 protein CTD PMID:20106945 aflatoxin B1 increases methylation ISO RGD:1607054 6480464 Aflatoxin B1 results in increased methylation of HACL1 gene CTD PMID:27153756 aflatoxin B1 decreases expression EXP 6480464 Aflatoxin B1 results in decreased expression of HACL1 mRNA CTD PMID:23630614 , PMID:33354967 aflatoxin B1 decreases expression ISO RGD:1607054 6480464 Aflatoxin B1 results in decreased expression of HACL1 mRNA CTD PMID:22100608 all-trans-retinoic acid decreases expression ISO RGD:1607054 6480464 Tretinoin results in decreased expression of HACL1 mRNA CTD PMID:33167477 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of HACL1 mRNA CTD PMID:16483693 Aroclor 1254 decreases expression EXP 6480464 Chlorodiphenyl (54% Chlorine) results in decreased expression of HACL1 mRNA CTD PMID:18178546 arsenous acid multiple interactions ISO RGD:1607054 6480464 Arsenic Trioxide inhibits the reaction [4-aminophenylarsenoxide binds to HACL1 protein] CTD PMID:26598702 atazanavir sulfate multiple interactions ISO RGD:1607054 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 benzene affects expression EXP 6480464 Benzene affects the expression of HACL1 mRNA CTD PMID:15878777 benzo[a]pyrene increases expression ISO RGD:1553280 6480464 Benzo(a)pyrene results in increased expression of HACL1 mRNA CTD PMID:19770486 benzo[a]pyrene decreases expression ISO RGD:1607054 6480464 Benzo(a)pyrene results in decreased expression of HACL1 mRNA CTD PMID:32234424 bis(2-chloroethyl) sulfide increases expression ISO RGD:1553280 6480464 Mustard Gas results in increased expression of HACL1 mRNA CTD PMID:15674844 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:1553280 6480464 PPARA protein promotes the reaction [Diethylhexyl Phthalate results in increased expression of HACL1 mRNA] CTD PMID:19850644 bis(2-ethylhexyl) phthalate increases expression ISO RGD:1553280 6480464 Diethylhexyl Phthalate results in increased expression of HACL1 mRNA CTD PMID:19245819 , PMID:19850644 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of HACL1 mRNA CTD PMID:25181051 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of HACL1 mRNA CTD PMID:30816183 more ... bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of HACL1 mRNA CTD PMID:30903817 buspirone increases expression EXP 6480464 Buspirone results in increased expression of HACL1 mRNA CTD PMID:24136188 C60 fullerene increases expression EXP 6480464 fullerene C60 results in increased expression of HACL1 mRNA CTD PMID:19167457 carbamazepine affects expression ISO RGD:1607054 6480464 Carbamazepine affects the expression of HACL1 mRNA CTD PMID:25979313 carbon nanotube decreases expression ISO RGD:1553280 6480464 Nanotubes more ... CTD PMID:25554681 carbon nanotube increases expression ISO RGD:1553280 6480464 Nanotubes more ... CTD PMID:25620056 carmustine decreases expression EXP 6480464 Carmustine results in decreased expression of HACL1 mRNA CTD PMID:16005536 chenodeoxycholic acid multiple interactions ISO RGD:1607054 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA, [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 cholesterol multiple interactions ISO RGD:1553280 6480464 [Cholesterol co-treated with 1, 2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of HACL1 mRNA CTD PMID:22129739 chromium trinitrate increases expression ISO RGD:1553280 6480464 chromium nitrate results in increased expression of HACL1 protein CTD PMID:22144121 chromium(6+) affects expression ISO RGD:1553280 6480464 chromium hexavalent ion affects the expression of HACL1 mRNA CTD PMID:28472532 cisplatin multiple interactions ISO RGD:1607054 6480464 [Cisplatin co-treated with jinfukang] results in increased expression of HACL1 mRNA CTD PMID:27392435 cisplatin increases expression ISO RGD:1607054 6480464 Cisplatin results in increased expression of HACL1 mRNA CTD PMID:27392435 clofibrate increases expression EXP 6480464 Clofibrate results in increased expression of HACL1 mRNA CTD PMID:12851107 clofibric acid affects expression EXP 6480464 Clofibric Acid affects the expression of HACL1 mRNA CTD PMID:17602206 cobalt dichloride decreases expression EXP 6480464 cobaltous chloride results in decreased expression of HACL1 mRNA CTD PMID:24386269 cyclosporin A decreases expression ISO RGD:1607054 6480464 Cyclosporine results in decreased expression of HACL1 mRNA CTD PMID:20106945 cyclosporin A decreases methylation ISO RGD:1607054 6480464 Cyclosporine results in decreased methylation of HACL1 promoter CTD PMID:27989131 cyclosporin A increases expression ISO RGD:1607054 6480464 Cyclosporine results in increased expression of HACL1 mRNA CTD PMID:25562108 decabromodiphenyl ether increases expression EXP 6480464 decabromobiphenyl ether results in increased expression of HACL1 mRNA CTD PMID:23640034 deoxycholic acid multiple interactions ISO RGD:1607054 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA, [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 diarsenic trioxide multiple interactions ISO RGD:1607054 6480464 Arsenic Trioxide inhibits the reaction [4-aminophenylarsenoxide binds to HACL1 protein] CTD PMID:26598702 dicrotophos decreases expression ISO RGD:1607054 6480464 dicrotophos results in decreased expression of HACL1 mRNA CTD PMID:28302478 dioxygen multiple interactions ISO RGD:1553280 6480464 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of HACL1 mRNA CTD PMID:30529165 doxorubicin increases expression ISO RGD:1607054 6480464 Doxorubicin results in increased expression of HACL1 mRNA CTD PMID:29803840 ethanol increases expression ISO RGD:1553280 6480464 Ethanol results in increased expression of HACL1 mRNA CTD PMID:30319688 flutamide decreases expression EXP 6480464 Flutamide results in decreased expression of HACL1 mRNA CTD PMID:24136188 folic acid decreases expression ISO RGD:1553280 6480464 Folic Acid results in decreased expression of HACL1 mRNA CTD PMID:25629700 furan increases methylation EXP 6480464 furan results in increased methylation of HACL1 gene CTD PMID:22079235 glafenine decreases expression EXP 6480464 Glafenine results in decreased expression of HACL1 mRNA CTD PMID:24136188 glycochenodeoxycholic acid multiple interactions ISO RGD:1607054 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA, [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 glycocholic acid multiple interactions ISO RGD:1607054 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA, [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 glycodeoxycholic acid multiple interactions ISO RGD:1607054 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA, [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 ivermectin decreases expression ISO RGD:1607054 6480464 Ivermectin results in decreased expression of HACL1 protein CTD PMID:32959892 methapyrilene decreases expression EXP 6480464 Methapyrilene results in decreased expression of HACL1 mRNA CTD PMID:30467583 methotrexate decreases expression EXP 6480464 Methotrexate results in decreased expression of HACL1 mRNA CTD PMID:16005536 Muraglitazar increases expression EXP 6480464 muraglitazar results in increased expression of HACL1 mRNA CTD PMID:21515302 N-nitrosodiethylamine decreases expression ISO RGD:1553280 6480464 Diethylnitrosamine results in decreased expression of HACL1 mRNA CTD PMID:24535843 N-nitrosodiethylamine multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of HACL1 mRNA CTD PMID:28943392 nickel atom decreases expression ISO RGD:1607054 6480464 Nickel results in decreased expression of HACL1 mRNA CTD PMID:25583101 nimesulide increases expression EXP 6480464 nimesulide results in increased expression of HACL1 mRNA CTD PMID:24136188 oxycodone increases expression EXP 6480464 Oxycodone results in increased expression of HACL1 mRNA CTD PMID:23439660 paclitaxel increases expression EXP 6480464 Paclitaxel results in increased expression of HACL1 mRNA CTD PMID:15585946 paracetamol affects expression ISO RGD:1553280 6480464 Acetaminophen affects the expression of HACL1 mRNA CTD PMID:17562736 paracetamol multiple interactions ISO RGD:1607054 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA CTD PMID:33819548 paracetamol multiple interactions ISO RGD:1553280 6480464 PANX1 gene mutant form promotes the reaction [Acetaminophen results in decreased expression of HACL1 mRNA] CTD PMID:29246445 paracetamol decreases expression ISO RGD:1553280 6480464 Acetaminophen results in decreased expression of HACL1 mRNA CTD PMID:29246445 perfluorooctanoic acid increases expression EXP 6480464 perfluorooctanoic acid results in increased expression of HACL1 mRNA, perfluorooctanoic acid results in increased expression of HACL1 protein CTD PMID:16221955 more ... pirinixic acid multiple interactions ISO RGD:1607054 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of HACL1 mRNA CTD PMID:19710929 pirinixic acid increases expression EXP 6480464 pirinixic acid results in increased expression of HACL1 mRNA CTD PMID:19162173 , PMID:22484513 pirinixic acid increases expression ISO RGD:1553280 6480464 pirinixic acid results in increased expression of HACL1 mRNA, pirinixic acid results in increased expression of HACL1 protein CTD PMID:15226431 more ... potassium chromate increases expression ISO RGD:1553280 6480464 potassium chromate(VI) results in increased expression of HACL1 protein CTD PMID:22144121 quercetin decreases expression ISO RGD:1607054 6480464 Quercetin results in decreased expression of HACL1 mRNA CTD PMID:21632981 resveratrol multiple interactions ISO RGD:1607054 6480464 [Plant Extracts co-treated with Resveratrol] results in increased expression of HACL1 mRNA CTD PMID:23557933 sodium arsenite decreases expression ISO RGD:1607054 6480464 sodium arsenite results in decreased expression of HACL1 mRNA CTD PMID:22714537 , PMID:25879800 sunitinib decreases expression ISO RGD:1607054 6480464 Sunitinib results in decreased expression of HACL1 mRNA CTD PMID:31533062 Tesaglitazar increases expression EXP 6480464 tesaglitazar results in increased expression of HACL1 mRNA CTD PMID:21515302 tetrachloroethene increases expression ISO RGD:1553280 6480464 Tetrachloroethylene results in increased expression of HACL1 mRNA CTD PMID:28973375 tetrachloromethane decreases expression ISO RGD:1553280 6480464 Carbon Tetrachloride results in decreased expression of HACL1 mRNA CTD PMID:27339419 , PMID:31919559 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of HACL1 mRNA CTD PMID:31150632 thioacetamide decreases expression EXP 6480464 Thioacetamide results in decreased expression of HACL1 mRNA CTD PMID:23411599 , PMID:34492290 thioacetamide multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of HACL1 mRNA CTD PMID:28943392 tioguanine decreases expression EXP 6480464 Thioguanine results in decreased expression of HACL1 mRNA CTD PMID:16005536 triphenyl phosphate decreases expression EXP 6480464 triphenyl phosphate results in decreased expression of HACL1 mRNA CTD PMID:30589522 troglitazone decreases expression ISO RGD:1553280 6480464 troglitazone results in decreased expression of HACL1 protein CTD PMID:18495193 troglitazone increases expression ISO RGD:1553280 6480464 troglitazone results in increased expression of HACL1 protein CTD PMID:18495193 troglitazone increases expression EXP 6480464 troglitazone results in increased expression of HACL1 mRNA CTD PMID:21515302 trovafloxacin increases expression EXP 6480464 trovafloxacin results in increased expression of HACL1 mRNA CTD PMID:24136188 tungsten increases expression ISO RGD:1553280 6480464 Tungsten results in increased expression of HACL1 mRNA CTD PMID:30912803 valproic acid increases expression ISO RGD:1553280 6480464 Valproic Acid results in increased expression of HACL1 mRNA CTD PMID:21427059 , PMID:24489787 valproic acid decreases expression ISO RGD:1607054 6480464 Valproic Acid results in decreased expression of HACL1 mRNA CTD PMID:23179753 , PMID:27188386 valproic acid affects expression ISO RGD:1607054 6480464 Valproic Acid affects the expression of HACL1 mRNA CTD PMID:25979313 zinc atom decreases expression EXP 6480464 Zinc deficiency results in decreased expression of HACL1 mRNA CTD PMID:15671213 zinc(0) decreases expression EXP 6480464 Zinc deficiency results in decreased expression of HACL1 mRNA CTD PMID:15671213